Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
17
5
2019
medline:
26
11
2019
entrez:
17
5
2019
Statut:
ppublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy. Computed tomography (CT) and/or MRI are commonly used for staging, however, the role of fluorine-18-fluorodeoxyglucose (F-FDG)-PET is not clearly established. In this study, we evaluated F-FDG-PET/CT imaging for initial staging of cSCC. F-FDG-PET/CT scans performed in patients with newly diagnosed cSCC were reviewed retrospectively. Images were visually assessed for lesions and F-FDG uptake [standardized uptake value (SUV)] in primary and secondary sites was measured. Suspected lesions on F-FDG-PET/CT were correlated with histopathology when available, follow-up imaging or clinical data in others. Twenty-three cSCC patients who underwent F-FDG-PET/CT at diagnosis were evaluated. Primary sites were in head/neck (n=21), chest (n=1), and foot (n=1). All patients had F-FDG-positive scans with a total of 51 F-FDG-positive lesions. All primary lesions (n=24) were F-FDG-positive (SUV: 2.3-22.8; mean 10.2), and additional 27 F-FDG-positive lesions, including 21 nodes, four cutaneous, one osseous and one lung lesion, were noted in 13 patients. Mean size of F-FDG-positive nodes was 0.9 cm (range: 0.4-2.5 cm), predominantly clinically impalpable. Pathology was available for 40/51 lesions; 31 sites positive for malignancy. SUV (mean±SD) was 9.2±6.2 for malignant and 2.7±1.2 for benign lesions. Sensitivity, positive predictive value, and accuracy of F-FDG-PET/CT scan were 100, 77.5, and 77.5%, respectively. F-FDG detected seven additional lesions in three patients, compared to CT/MRI. Overall, staging F-FDG-PET/CT detected nine prior unknown lesions in five patients that were proven metastatic disease by histopathology or follow-up; F-FDG-PET/CT modified management in 5/23 (21.7%) patients. F-FDG-PET/CT has high sensitivity in the detection of cSCC lesions, including small cutaneous and nodal disease, and has a potential role in initial staging and management.
Sections du résumé
BACKGROUND
BACKGROUND
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin malignancy. Computed tomography (CT) and/or MRI are commonly used for staging, however, the role of fluorine-18-fluorodeoxyglucose (F-FDG)-PET is not clearly established. In this study, we evaluated F-FDG-PET/CT imaging for initial staging of cSCC.
PATIENTS AND METHODS
METHODS
F-FDG-PET/CT scans performed in patients with newly diagnosed cSCC were reviewed retrospectively. Images were visually assessed for lesions and F-FDG uptake [standardized uptake value (SUV)] in primary and secondary sites was measured. Suspected lesions on F-FDG-PET/CT were correlated with histopathology when available, follow-up imaging or clinical data in others.
RESULTS
RESULTS
Twenty-three cSCC patients who underwent F-FDG-PET/CT at diagnosis were evaluated. Primary sites were in head/neck (n=21), chest (n=1), and foot (n=1). All patients had F-FDG-positive scans with a total of 51 F-FDG-positive lesions. All primary lesions (n=24) were F-FDG-positive (SUV: 2.3-22.8; mean 10.2), and additional 27 F-FDG-positive lesions, including 21 nodes, four cutaneous, one osseous and one lung lesion, were noted in 13 patients. Mean size of F-FDG-positive nodes was 0.9 cm (range: 0.4-2.5 cm), predominantly clinically impalpable. Pathology was available for 40/51 lesions; 31 sites positive for malignancy. SUV (mean±SD) was 9.2±6.2 for malignant and 2.7±1.2 for benign lesions. Sensitivity, positive predictive value, and accuracy of F-FDG-PET/CT scan were 100, 77.5, and 77.5%, respectively. F-FDG detected seven additional lesions in three patients, compared to CT/MRI. Overall, staging F-FDG-PET/CT detected nine prior unknown lesions in five patients that were proven metastatic disease by histopathology or follow-up; F-FDG-PET/CT modified management in 5/23 (21.7%) patients.
CONCLUSION
CONCLUSIONS
F-FDG-PET/CT has high sensitivity in the detection of cSCC lesions, including small cutaneous and nodal disease, and has a potential role in initial staging and management.
Identifiants
pubmed: 31095044
doi: 10.1097/MNM.0000000000001029
pmc: PMC7518232
mid: NIHMS1527778
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
744-751Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
J Natl Cancer Inst. 2008 May 21;100(10):712-20
pubmed: 18477804
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
Am J Otolaryngol. 2014 May-Jun;35(3):347-52
pubmed: 24503246
Dermatol Surg. 2005 Apr;31(4):442-6; discussion 446-7
pubmed: 15871320
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
J Am Acad Dermatol. 2013 Apr;68(4):592-599
pubmed: 23127473
JAMA Dermatol. 2016 Apr;152(4):419-28
pubmed: 26762219
Arch Dermatol. 2003 Sep;139(9):1141-6
pubmed: 12975155
J Am Acad Dermatol. 2017 Feb;76(2):217-225
pubmed: 27707594
J Am Acad Dermatol. 2016 Jul;75(1):186-96
pubmed: 26992283
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Head Neck. 2013 Aug;35(8):1138-43
pubmed: 23152126
Nucl Med Commun. 2016 May;37(5):446-52
pubmed: 26657218
Am J Clin Dermatol. 2016 Oct;17(5):491-508
pubmed: 27358187
Lancet Oncol. 2008 Aug;9(8):713-20
pubmed: 18617440
AJR Am J Roentgenol. 2010 Aug;195(2):281-9
pubmed: 20651182
J Natl Cancer Inst. 2008 May 21;100(10):688-9
pubmed: 18477798
Otolaryngol Head Neck Surg. 2000 Sep;123(3):324-7
pubmed: 10964315
J Am Acad Dermatol. 2018 Feb;78(2):237-247
pubmed: 29332704
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
Int J Surg Pathol. 2015 Sep;23(6):447-53
pubmed: 26092229
World J Surg Oncol. 2011 Jul 19;9:80
pubmed: 21771334
BMC Cancer. 2014 Mar 19;14:210
pubmed: 24645632
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Head Neck. 2011 Apr;33(4):469-75
pubmed: 20645285
J Dermatol. 2016 Nov;43(11):1314-1320
pubmed: 27060693
Otolaryngol Head Neck Surg. 2018 Jan;158(1):122-126
pubmed: 28925330